Search for: "Boehringer Ingelheim Pharmaceuticals, Inc."
Results 1 - 20
of 124
Sort by Relevance
|
Sort by Date
11 Jan 2024, 12:03 am
The FIE determination released in fall 2023 involves the Reference Product AbbVie’s Humira (adalimumab) and two interchangeable biosimilars—first approved is Cyltezo (adalimumab-adbm), filed by Boehringer Ingelheim Pharmaceuticals, Inc, which was followed by Abrilada (adalimumab-afzb), filed by Pfizer. [read post]
13 Nov 2023, 4:10 pm
Boehringer Ingelheim Pharmaceuticals, Inc., Williams asks the court to grant review and reverse the 11th Circuit’s ruling. [read post]
9 Nov 2020, 3:00 am
Currently, the defendants in active Zantac cancer injury cases include: Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
9 Nov 2020, 3:00 am
Currently, the defendants in active Zantac cancer injury cases include: Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
9 Nov 2020, 3:00 am
Currently, the defendants in active Zantac cancer injury cases include: Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
5 Apr 2020, 9:57 pm
By Donald Zuhn –- Last month, in Boehringer Ingelheim Pharmaceuticals Inc. v. [read post]
30 Jan 2020, 5:29 am
The Zantac litigation effort involves several international drug companies, including Boehringer Ingelheim Pharmaceuticals (based in Connecticut); Boehringer Ingelheim Corporation (German parent company); Sanofi US Services, Inc. [read post]
30 Jan 2020, 5:29 am
The Zantac litigation effort involves several international drug companies, including Boehringer Ingelheim Pharmaceuticals (based in Connecticut); Boehringer Ingelheim Corporation (German parent company); Sanofi US Services, Inc. [read post]
13 Nov 2019, 9:15 am
” Similarly, the Board held in Mylan Pharmaceuticals Inc. v. [read post]
1 Aug 2019, 8:30 am
Boehringer Ingelheim Corp., et al., a $150 million settlement with GlaxoSmithKline PLC, and a $190 million settlement with Aventis Pharmaceuticals, Inc. [read post]
4 Sep 2018, 7:00 am
Boehringer Ingelheim Pharmaceuticals, Inc., 892 F.3d 1264 (D.C. [read post]
4 Sep 2018, 7:00 am
Boehringer Ingelheim Pharmaceuticals, Inc., 892 F.3d 1264 (D.C. [read post]
9 Jul 2018, 6:30 pm
Boehringer Ingelheim Pharmaceuticals, Inc., 2018 WL 3028972 (CADC June 19, 2018). [read post]
9 Jul 2018, 6:30 pm
Boehringer Ingelheim Pharmaceuticals, Inc., 2018 WL 3028972 (CADC June 19, 2018). [read post]
11 Jan 2018, 12:30 pm
Boehringer Ingelheim Pharmaceuticals, Inc. is the drug company responsible for OFEV in the US. [read post]
TTAB Test: Is "BREATHLESS" Merely Descriptive of Idiopathic Pulmonary Fibrosis Information Services?
29 Nov 2017, 3:29 am
In re Boehringer Ingelheim Pharmaceuticals, Inc., Serial No. 86852106 (November 27, 2017) [not precedential] (Opinion by Judge Frances Wolfson).The Board ignored applicant's feeble double entendre argument, but it agreed with applicant that the USPTO's evidence failed to show that the term "breathless" merely describes the subject services. [read post]
10 Oct 2017, 7:10 am
" Boehringer Ingelheim Pharmaceuticals, Inc. et al v. [read post]
21 Mar 2017, 12:23 pm
Boehringer Ingelheim Pharmaceuticals, Inc. markets this prescription anticoagulant drug. [read post]
30 Dec 2016, 2:58 pm
Permission to appeal in patent cases - farewell to the Pozzoli approachGuest Kat Eibhlin Vardy recaps the case Teva UK Ltd v Boehringer Ingelheim Pharma GmbH & Co KG, [2016] EWCA Civ 1296. [read post]
22 Aug 2016, 1:05 pm
You may be entitled to compensation for your medical bills, lost wages, pain and suffering and other damages that can be pursued in a defective drug lawsuit against the manufacturer of Pradaxa, Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
